MedTrace Logo

A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

NCT05225207 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 658

Last updated 2023-01-09

No results posted yet for this study

Summary

The purpose of this study is to describe the following safety and the efficacy of Lenvima for the first-line treatment indication of participants with uHHC in the post marketing setting: (1) Serious adverse events and serious adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in the precautions for use (3) Known adverse drug reactions (4) Non-serious adverse drug reactions (5) Other safety and efficacy related information.

Conditions

  • Liver Neoplasms
  • Carcinoma, Hepatocellular

Interventions

OTHER

Non-interventional

No intervention will be administered.

Sponsors & Collaborators

  • Eisai Korea Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-28
Primary Completion
2022-01-31
Completion
2022-01-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05225207 on ClinicalTrials.gov